Chi-square tests were performed to study the relationships between CD8+ T cell, CD8+PD-L1+ T cell, or CD68+CD163+ M2 macrophage infiltration and the response rate of NSCLC patients who received ICI therapy. This evidence concerns the gene CD163 and non-small cell lung carcinoma.